![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/08/01/2922906/0/en/Elevar-Therapeutics-Granted-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-First-Line-Systemic-Therapy-for-Unresectable-Hepatocellular-Carcinoma.html
https://www.fiercepharma.com/pharma/fda-pd-1-combo-elevar-hengrui-camrelizumab-liver-cancer
https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html
https://www.globenewswire.com/news-release/2023/08/03/2718088/0/en/Elevar-Therapeutics-to-Host-August-10-Virtual-KOL-Event-on-Phase-3-Study-of-Rivoceranib-in-Combination-with-Camrelizumab-in-Unresectable-Hepatocellular-Carcinoma-uHCC.html
https://www.globenewswire.com/news-release/2023/07/17/2705640/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-for-Filing-of-New-Drug-Application-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Treatment-for-Unresectable-Hepatoce.html
https://www.globenewswire.com/news-release/2023/05/17/2670874/0/en/Elevar-Therapeutics-Submits-New-Drug-Application-to-FDA-for-Combination-of-Rivoceranib-and-Camrelizumab-as-First-Line-Treatment-Option-for-Unresectable-Hepatocellular-Carcinoma.html
https://www.globenewswire.com/news-release/2023/03/16/2628617/0/en/Elevar-Therapeutics-to-Present-Clinically-Supported-Poster-at-AACR-2023-Demonstrating-Rivoceranib-as-a-Potent-and-Most-Selective-TKI-for-VEGFR-2.html
https://www.globenewswire.com/news-release/2022/10/11/2532328/0/en/Elevar-Therapeutics-Announces-Positive-Pre-NDA-Meeting-for-Rivoceranib-Combination-With-Camrelizumab-as-Hepatocellular-Carcinoma-Treatment-Option.html
https://www.globenewswire.com/news-release/2022/10/11/2532307/0/en/Avenue-Therapeutics-Announces-Closing-of-12-Million-Underwritten-Public-Offering.html
https://www.prnewswire.com/news-releases/camrelizumab-in-combination-with-rivoceranib-apatinib-significantly-prolonged-overall-survival-and-progression-free-survival-vs-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-in-a-multinational-phase-3-trial--301621486.html
https://www.globenewswire.com/news-release/2022/09/07/2512048/0/en/Elevar-Therapeutics-Announces-Camrelizumab-Plus-Rivoceranib-Significantly-Prolonged-Overall-Survival-and-Progression-Free-Survival-Versus-Sorafenib-in-Patients-With-Unresectable-He.html
https://www.globenewswire.com/news-release/2022/06/06/2457220/0/en/Elevar-Therapeutics-Shares-Results-of-Phase-2-Rivoceranib-Trial-in-Patients-with-Progressive-Recurrent-or-Metastatic-Adenoid-Cystic-Carcinoma.html
https://www.fiercepharma.com/pharma/another-chinese-pd-1-immunotherapy-eyes-fda-application-hengrui-touts-win-liver-cancer
http://www.pharmafile.com/news/594711/hlb-s-liver-cancer-treatment-awarded-orphan-drug-status-fd